Yuzuru Sasamoto

Inhibition of PLK1 helps to restrict c-Met-induced growth and therapeutic resistance of renal cancer cells

Acquired therapeutic resistance is a major problem in the treatment of advanced renal cell carcinoma (RCC). The receptor tyrosine kinase (RTK) c-Met is hyperactive in RCC and plays a major role in the survival of tumor cells during therapy-induced oxidative stress. Although c-Met...